JP2008540552A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540552A5
JP2008540552A5 JP2008511301A JP2008511301A JP2008540552A5 JP 2008540552 A5 JP2008540552 A5 JP 2008540552A5 JP 2008511301 A JP2008511301 A JP 2008511301A JP 2008511301 A JP2008511301 A JP 2008511301A JP 2008540552 A5 JP2008540552 A5 JP 2008540552A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
composition according
brimonidine
administered
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008511301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540552A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/018019 external-priority patent/WO2006122165A2/en
Publication of JP2008540552A publication Critical patent/JP2008540552A/ja
Publication of JP2008540552A5 publication Critical patent/JP2008540552A5/ja
Pending legal-status Critical Current

Links

JP2008511301A 2005-05-10 2006-05-09 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 Pending JP2008540552A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67977105P 2005-05-10 2005-05-10
PCT/US2006/018019 WO2006122165A2 (en) 2005-05-10 2006-05-09 Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011209152A Division JP2012046530A (ja) 2005-05-10 2011-09-26 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療

Publications (2)

Publication Number Publication Date
JP2008540552A JP2008540552A (ja) 2008-11-20
JP2008540552A5 true JP2008540552A5 (https=) 2011-06-16

Family

ID=37397258

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008511301A Pending JP2008540552A (ja) 2005-05-10 2006-05-09 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2011209152A Pending JP2012046530A (ja) 2005-05-10 2011-09-26 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2014156852A Pending JP2015013863A (ja) 2005-05-10 2014-07-31 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011209152A Pending JP2012046530A (ja) 2005-05-10 2011-09-26 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2014156852A Pending JP2015013863A (ja) 2005-05-10 2014-07-31 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療

Country Status (8)

Country Link
US (3) US7931909B2 (https=)
EP (2) EP3656374A1 (https=)
JP (3) JP2008540552A (https=)
AU (1) AU2006244083A1 (https=)
BR (1) BRPI0608978A2 (https=)
CA (1) CA2603069C (https=)
ES (1) ES2798259T3 (https=)
WO (1) WO2006122165A2 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
CA2850858A1 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8492334B2 (en) * 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) * 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010118340A1 (en) * 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
DK2498783T3 (en) 2009-11-09 2018-12-10 Allergan Inc COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8653123B2 (en) 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
CN103370326B (zh) 2010-12-16 2016-05-11 阿勒根公司 作为趋化因子受体调节剂的磷衍生物
KR101840503B1 (ko) 2010-12-16 2018-03-20 알러간, 인코포레이티드 케모카인 수용체 조절제로서의 신규한 1,2-비스-설폰아마이드 유도체
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
AU2012214265A1 (en) 2011-02-11 2013-09-05 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
US20130190324A1 (en) * 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
US20130197002A1 (en) 2012-01-30 2013-08-01 Allergan, Inc. Brimonidine for treating visual disorders mediated by central visual projections from the eye
HUE038700T2 (hu) 2012-03-01 2018-11-28 Allergan Inc Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk
RU2676102C2 (ru) 2012-09-27 2018-12-26 Аллерган, Инк. Биодеградируемые системы доставки лекарственных средств для долговременного высвобождения белков
CN112932781A (zh) * 2013-01-15 2021-06-11 科罗拉多州立大学董事会, 公司实体 泪腺系统给药装置
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
WO2014159657A1 (en) 2013-03-12 2014-10-02 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
AU2014240139A1 (en) 2013-03-15 2015-09-17 Acadia Pharmaceuticals Inc. Muscarinic agonists
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
AR098583A1 (es) 2013-12-02 2016-06-01 Allergan Inc Compuesto de sulfonamida de benzotiofeno, composición farmacéutica que lo comprende y su uso para la preparación de dicha composición
KR101587483B1 (ko) * 2014-03-28 2016-01-21 동아대학교 산학협력단 미토콘드리아성 복합체 ⅰ 저해제를 유효성분으로 함유하는 증식성 유리체망막병증의 예방 또는 치료용 약학적 조성물
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
AU2016359288C1 (en) 2015-11-23 2022-03-17 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
WO2017201255A1 (en) 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device
EP4520828A3 (en) 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
KR20190110101A (ko) * 2016-12-27 2019-09-27 더 유니버시티 오브 유타 리서치 파운데이션 안구내 약물 전달 장치 및 관련 방법들
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
US20230301993A1 (en) * 2020-08-21 2023-09-28 Vyluma Inc. Low-Dose Ophthalmic Compositions and Methods
JP2023541372A (ja) * 2020-08-21 2023-10-02 オクロセラピー リミテッド ライアビリティ カンパニー 神経保護方法及びその使用
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
JP2001513369A (ja) 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
AU2003214133A1 (en) 2002-03-18 2003-09-29 Novartis Ag Topical composition comprising a cyclofructan, a carrier and a drug
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction

Similar Documents

Publication Publication Date Title
JP2008540552A5 (https=)
Allyn et al. Considerations for polymers used in ocular drug delivery
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP6700348B2 (ja) 持続型薬物送達インプラント
AU2007223057B2 (en) Ocular therapy using sirtuin-activating agents
Nanjawade et al. RETRACTED: In situ-forming hydrogels for sustained ophthalmic drug delivery
US20130071349A1 (en) Biodegradable polymers for lowering intraocular pressure
KR20070083941A (ko) 중합체 전달 조성을 갖는 눈 전달
JP2012046530A (ja) 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
TW200826943A (en) Intraocular drug delivery systems
CN101394834A (zh) 用糖皮质激素衍生物选择性渗透后段组织来治疗眼睛
JP2007535539A (ja) β−アドレナリン受容体拮抗薬を含む持続放出眼内インプラントおよび眼の神経障害の治療方法
JP2009535422A5 (https=)
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
US20150141348A1 (en) SUSTAINED RELEASE siRNA FOR OCULAR DRUG DELIVERY
JP2024167340A (ja) コーティング眼用インプラント
Rajput et al. Processed Excipients in Ocular Drug Delivery
JPH1170138A (ja) ポリ乳酸強膜プラグ
AU2011239238B2 (en) Ocular therapy using sirtuin-activating agents
Robinson Degradable Polymer Constructs Delivering AG1478 to Promote Axon Regeneration in the Mature Mammalian Central Nervous System